Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 2" (PIGFP2) does not correspond to a functional gene, enzyme, receptor, or recognized therapeutic target in current scientific databases. The likely intended target is PIGP, which is a subunit of the GPI-N-acetylglucosaminyltransferase complex essential for GPI-anchor biosynthesis in humans[1]. There is no specific protein, function, or disease association for "PIGFP2" in the peer-reviewed literature or authority resources as of the current knowledge cutoff. If you need structured information on the actual GPI-anchor biosynthesis genes, such as PIGP or PIGF, please clarify. Otherwise, there is no validated bioactive "PIGFP2" entity in human biology[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 2 (PIGFP2).